COVID-19 Drug Treatment in China
- PDF / 312,713 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 18 Downloads / 144 Views
HOT TOPIC
COVID-19 Drug Treatment in China Linzi Fan 1 & Shuang Jiang 1 & Xinrong Yang 1 & Zhibin Wang 2 & Chunjuan Yang 1
# Springer Nature Switzerland AG 2020
Abstract Purpose of Review An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19. Recent Findings At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress. Summary In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19. Keywords COVID-19 . SARS-CoV-2 . Medical treatment . New drug research and development
Introduction An outbreak of a series of pneumonia cases associated with a novel coronavirus has been reported in Wuhan, Hubei Province, China, since December 2019 [1–3]. It is highly contagious and has rapidly spread to the entire China and multiple other countries worldwide since then [4–6]. On January 5,
* Zhibin Wang [email protected] * Chunjuan Yang [email protected] Linzi Fan [email protected] Shuang Jiang [email protected] Xinrong Yang [email protected] 1
Department of Pharmaceutical Analysis and Analytical Chemistry, College of Pharmacy, Harbin Medical University, No. 157 Baojian Road, Nangang District, Harbin 150081, Heilongjiang, People’s Republic of China
2
Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang, China
2020, Professor Zhang of Fudan University completed virus sequencing and submitted the first novel coronavirus genome sequence to the National Bank of the US National Center for Biotechnology Information (Acc. No. MN908947). After that, this global health threat was officially and internationally named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020 [7]. On January 30, 2020, the WHO declared the Chinese outbreak of COVID-19 to be a public health emergency of international concern, which means the outbreak of COVID-19 raised intense attention internationally; all countries around the world should be prepared for a potential global outbreak [8–10]. Up to now, there had been 1,524,334 confirmed cases, 340,335 cured, and 88,468 deaths (as of April 9, 2020). Clinically, most patients developed mild symptoms of dry cough, dyspnea, fever, and bilateral lung infiltrates on imaging [11–13]. Besides, numbers of researches have confirmed that while the mortality rate of the elderly and patients with underlying diseases is high, that of the young is relatively low through the
Data Loading...
